Optimization of Formability Process of Compound Lipid Lowering Tablets by Response Surface Methodology and Its Lipid Lowering Activity

ZHANG Rongrong; MA Xintong; WANG Miao; ZHANG Hongyin; YI Chunguang; YAN Mingming; ZHAO Daqing

doi:10.13386/j.issn1002-0306.2020030167

Volume 42 Issue 3

Jan. 2021

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2021 > 42(3): 115-121,126. > DOI: 10.13386/j.issn1002-0306.2020030167

ZHANG Rongrong, MA Xintong, WANG Miao, ZHANG Hongyin, YI Chunguang, YAN Mingming, ZHAO Daqing. Optimization of Formability Process of Compound Lipid Lowering Tablets by Response Surface Methodology and Its Lipid Lowering Activity[J]. Science and Technology of Food Industry, 2021, 42(3): 115-121,126. DOI: 10.13386/j.issn1002-0306.2020030167

Citation:

PDF (1928 KB)

Optimization of Formability Process of Compound Lipid Lowering Tablets by Response Surface Methodology and Its Lipid Lowering Activity

1. Changchun University of Chinese Medicine, Jilin Ginseng Academy, Changchun 130117, China;
2. School of Pharmaceutical Sciences Changchun University of Chinese Medicine, Changchun 130117, China;
3. The College of Basic Medical of Changchun University of Chinese Medicine, Changchun 130117, China;
4. Jinlin Provincial Science and Technology Innovation Center of Health Food of Chinese Medicine, Changchun 130117, China

More Information

Received Date: March 15, 2020
Available Online: February 02, 2021

Graphical Abstract

Abstract

Abstract

Objective:To optimize the moldability process of compound lipid lowering tablets and to study its lipid-lowering activity. Methods:Using Box-behnken response surface method,the compound lipid lowering tablet extract as the main drug,with the friability,disintegration time and dissolution rate as the evaluation indicators,the ratio of the main drug to the filler,the amount of disintegrant and the concentration of ethanol as the influencing factor,the moldability process of compound lipid lowering tablets were optimized. At the same time,the hyperlipemia rat model was used to evaluate the lipid-lowering activity of compound lipid lowering tablets. Results:The ratio of main drug and auxiliary materials was 80∶15,the amount of disintegrant was 5%,and the concentration of ethanol was 80%.Verification experiment results:The comprehensive score of each batch was 94.01%,and the relative error with the predicted value was 1.49%,and the friability and disintegration time limit were in compliance with pharmacopoeia. Lipid lowering activity test results:Compared with the experimental data of high-fat model group,except for high-density lipoprotein(HDL-C),other indexes in serum of rats in each dose group of compound lipid lowering tablet showed a downward trend,among which the levels of each index in high-dose group significantly decreased(P<0.01),AST and ALT levels in medium dose group significantly decreased(P<0.01),TC,TG and LDL-C levels significantly decreased(P<0.01).The level of HDL-C in medium dose group increased,and had significant difference with the model group(P<0.05). Conclusion:The preferred molding process of this experiment is stable and feasible,and the lipid lowering activity of compound lipid lowering tablets is good. The results of this study provide a reliable basis for the production and development of compound lipid lowering tablets.
- compound lipid lowering tablet,
- formability process,
- Box-behnken,
- response surface method,
- hyperlipidemia,
- lipid lowering activity

FullText(HTML)

References (25)

References

[1]	王福刚,曹娟,刘斌,等.荷叶的化学成分及其药理作用研究进展[J].时珍国医国药,2010,21(9):2339-2340.
[2]	冯彦.丹参的现代药理研究及临床应用[J].中医临床研究,2017,9(30):46-47.
[3]	史海波.丹参多酚酸盐和三七总甙诱导血管新生作用及对大鼠心肌缺血的保护作用[D].南京:南京医科大学,2015.
[4]	张建永,晏仁义,王岚,等.丹参山楂有效组分配伍抗动脉粥样硬化的实验研究[J].中国中药杂志,2013,38(12):1987-1991.
[5]	薛洁,谢梅林,顾振纶,等.丹参和山楂提取物含药血清对胆固醇代谢的影响[J].中草药,2007,38(1):73-77.
[6]	王永,粱宇明.三七、丹参、山楂粉结合阿托伐他汀治疗高脂血症临床疗效研究[J].中国医药科学,2018,8(10):39-41 ,88.
[7]	刘涛,冯晶晶,李鹏程,等.元胡止痛系列制剂4种工艺比较[J].中成药,2017,39(4):851-854.
[8]	周光姣,黄翔,冯学花.复方五花颗粒制备工艺的优化[J].中成药,2019,41(6):1389-1391.
[9]	弓佩含,杨洋,刘玉婷,等.复方人参增氧分散片的成型工艺研究[J].中华中医药杂志,2018,33(8):3609-3613.
[10]	宁波,于丽颖,王晓林,等.响应曲面法优化超声波提取玉竹总皂苷的工艺研究[J].食品工业科技,2017,38(1):234-237.
[11]	Hirunpanich V,Utaipat A,Morales N P,et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats[J].Journal of Ethnopharmacology,2006,103(2):252-260.
[12]	雷燕妮.黄芩总黄酮对高血脂大鼠的降血脂作用研究[J].动物医学进展,2014,35(7):64-68.
[13]	谢玲,胡小军,訾璐,等.三七降脂粉对高脂血症合并脂肪肝患者降血脂作用的影响研究[J].世界中医药,2016,11(10):2002-2004 ,2008.
[14]	刁艳玲,班俊峰,谢清春,等.2种制备工艺对复方芪术颗粒成型性的影响[J].中成药,2017,39(2):414-417.
[15]	李娅丽,张越非,刘哲,等.响应曲面法优化人参皂苷及多糖微波辅助提取工艺[J].中国医药导报,2015,12(16):42-47.
[16]	王晶晶.中国七省(市)老年人高脂血症患病率、治疗率及影响因素研究[D].合肥:安徽医科大学,2014.
[17]	Wu H L,Chen Y L,Yu Y Y,et al. Ilex latifolia Thunb protects mice from HFD-induced body weight gain[J].Scientific Reports,2017,7:14660.
[18]	Xie Y D,Liu J P,Wang W,et al. 3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing,antioxidant,hypoglycemic and hypolipidemic effects[J].Bioorganic & Medicinal Chemistry Letters,2020,30(15):127277.
[19]	Sarwar R,Pierce N,Koppe S.Obesity and nonalcoholic fatty liver disease:Current perspectives[J].Diabetes,Metabolic Syndrome and Obesity:Targets and Therapy,2018,11:533-542.
[20]	王洁,杨旋,乔治园,等.中医药治疗非酒精性脂肪性肝病的研究进展[J].新疆中医药,2018,36(2):145-147.
[21]	李剑虹,王丽敏,李镒冲,等.2010年我国成年人血脂异常流行特点[J].中华预防医学杂志,2012,46(5):414-418.
[21]	Reiner Ž.Hypertriglyceridaemia and risk of coronary artery disease[J].Nature Reviews Cardiology,2017,14(7):401-411.
[23]	卓冰帆,张彦卿,张敏.山荷降脂汤治疗痰湿内阻型高脂血症合并脂肪肝的临床研究[J].时珍国医国药,2019,30(6):1426-1428.
[24]	董妙音,李万武,孔维宝,等.响应面法优化超声波辅助提取文冠果种皮总皂苷的工艺[J].中国油脂,2014,39(11):74-78.
[25]	张娜,胡丽娟,徐红欣,等.中药分散片制备工艺的研究进展[J].中国医院药学杂志,2011,31(11):930-932.